Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Tokyo, September 30, 2015 - Astellas Pharma Inc. (TSE: 4503; President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that it submitted a supplemental new drug application for...
Tokyo and North Brunswick, N.J., Sept 30th, 2015 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Chromocell Corporation (CEO: Christian Kopfli,...
Read more about Astellas donates ambulances on First-Aid Day (September 9)
Read more about Notice of Completion of Acquisition of Own Shares
Tokyo, Japan, July 31, 2015 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, collectively with its affiliates, hereinafter called “Astellas”) announced the launch of the Real...
Read more about Astellas Establishes New Real World Informatics and Analytics Function
NORTHBROOK, Ill., July 30, 2015 – Astellas today announced topline results from the Phase 3 ACTIVE study evaluating the efficacy and safety of intravenous (IV) and oral isavuconazole,...
Read more about Notice of Completion of Acquisition of Own Shares
Read more about Astellas Announces Status of Acquisition of Own Shares
Read more about Astellas Announces Status of Acquisition of Own Shares
Astellas Pharma Inc. (“Astellas”; TSE 4503, headquarters: Tokyo; President and CEO Yoshihiko Hatanaka) and Anokion SA (“Anokion“, headquarters: Lausanne; Chairman Jeffrey A. Hubbell) today...
TOKYO and NORTHBROOK, Ill. – June 1, 2015 – Astellas Pharma Inc. (Tokyo: 4503) announced that data from a Phase 2 study evaluating the investigational use of enzalutamide as a single agent for...
Read more about Astellas Announces Acquisition of Own Shares
Tokyo, May 8, 2015– Astellas Pharma Inc. (Headquarters: Tokyo; President and CEO: Yoshihiko Hatanaka, “Astellas”) would like to express our deepest sympathy to the victims of Nepal...
Read more about Astellas Supports Nepal Earthquake Relief Efforts
Tokyo, Japan, 23 April, 2015-The additional analyses of C-OPERA, and long-term safety and efficacy over 4 years in J-RAPID and HIKARI studies were reported at the Annual General Assembly and...
Tokyo and Cambridge, MA – April 22, 2015 -- Astellas Pharma Inc. (Tokyo: 4503) and Potenza Therapeutics, Inc., a biotechnology company developing a portfolio of immuno-oncology programs, today...
MSD K.K. (Head office: Tokyo; President: Tony Alvarez) and Astellas Pharma Inc. (Head office: Tokyo; President: Yoshihiko Hatanaka) signed a memorandum of understanding regarding co-development...
TOKYO and HOUSTON – April 3, 2015 – Astellas Pharma Inc. (TSE: 4503) and The University of Texas MD Anderson Cancer Center today announced the signing of an option agreement to research and...
SAN FRANCISCO, CA and TOKYO, JAPAN – April 2, 2015 – Medivation, Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. (TSE: 4503) today announced topline results from the Phase 2 STRIVE trial...
Tokyo, Japan, April 1, 2015 – Astellas Pharma Inc. (Tokyo:4503,“Astellas”) is pleased to announce that the Company will mark its 10th anniversary on April 1, 2015. Since being established in...
Tokyo, March 17, 2015 - Astellas Pharma Inc. (“Astellas”; Tokyo:4503; President and CEO: Yoshihiko Hatanaka) today announced that it submitted a supplemental new drug application for...
Read more about Notice of Completion of Acquisition of Own Shares
NORTHBROOK, Ill., March 6th, 2015, – Astellas today announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for the use of CRESEMBA®...
Follow us
